The use of different formulations of tocilizumab in the treatment of patients with moderate to severe COVID-19

The objective of the study : to compare changes in blood level C-reactive protein (CRP) during administration different formulations tocilizumab (TCZ) COVID-19 patients admitted hospital real clinical practice. Subjects and methods . cohort 14 was included retrospective study; they all had a severe course were hospital: 7 received intravenous infusions subcutaneous injections. indication for prescription elevation CRP by 5 times more or 2-fold ferritin above norm. In group receiving injections with tocilizumab, proportion elderly people bigger levels higher versus infusions. efficacy assessed on 1st, 3rd 7th day after administration. only discharged from improvement their state. Results. It has been demonstrated that when develop cytokine storm, use both (for administration) is effective. When administered intravenously, (especially at high rates - than 150 mg/l) intense these same long-term efficacy: decreased comparably groups, time complete normalization this rate did not differ significantly. dynamics decrease each specific case could be associated formulation drug other factors established.